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Medulloblastoma (MB) is the most common malignant brain tumor of pediatric age and is characterized by cells expressing stem,
astroglial, and neuronal markers. Among them, stem-like cells (hMB-SLCs) represent a fraction of the tumor cell population with
the potential of self-renewal and proliferation and have been associated with tumor poor prognosis. In this context, microRNAs
have been described as playing a pivotal role in stem cells differentiation. In our paper, we analyze microRNAs profile and genes
expression of hMB-SLCs before and after Retinoic Acid- (RA-) induced differentiation. We aimed to identify pivotal players of
specific pathways sustaining stemness and/or tumor development and progression and integrate the results of our recent proteomic
study. Our results uncovered 22 differentially expressed microRNAs that were used as input together with deregulated genes
and proteins in the Genomatix Pathway System (GePS) analysis revealing 3 subnetworks that could be interestingly involved
in the maintenance of hMB-SLCs proliferation. Taken together, our findings highlight microRNAs, genes, and proteins that are
significantly modulated in hMB-SLCs with respect to their RA-differentiated counterparts and could open new perspectives for
prognostic and therapeutic intervention on MB.
1. Introduction
Aggressive multimodal therapy has significantly improved
medulloblastoma (MB) outcomes but up to 30% of the cases
still recur and treated patients got debilitating secondary
sequelae [1]. MB is characterized by significant intratu-
moral heterogeneity and comprised of cells expressing stem,
astroglial, and neuronal markers whose contribution to
tumor expansion has not been completely understood yet [2].
Our and other laboratories have provided evidence that MB
harbors a distinct subpopulation of stem cells or cancer stem-
like cells (SLCs) [3, 4] identified by the marker expression
of Nanog [3]. Importantly stem cell signatures have been
associated with tumor poor prognosis and, very recently,
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we characterized SLCs in MB with aggressive behavior [1].
Interestingly, it has been reported that clonal genetic events
observed in metastases can be demonstrated in a restricted
subclone of the primary tumor, suggesting that only rare cells
have the ability to metastasize [5]. SLCs have been proposed
as themajor source of resistance toward conventional therapy
[6] and a never-ending reservoir for cancer maintenance and
progression [7]. Knowledge of the SLCs molecular features
is urgently needed to understand tumor progression and to
design novel stem specific therapeutic strategies. About this
topic, we previously isolated SLCs from human MBs (hMB-
SLCs) [1, 3] andmore recently investigated the proteomic pro-
file of hMB-SLCs and of their RA-differentiated counterparts
applying a label-free quantitative proteomic analysis able to
maximize the identification capacities of the statistically dif-
ferential spectral features [8]. In MBmicroRNAs, noncoding
RNAs that control gene expression [9] have been described
as being deregulated with respect to normal cerebellum
[10], form regulatory networks with components of signaling
pathways deregulated in cancer cells [11], and have also been
described to play a pivotal role in stem cell differentiation
[12]. In new experiments we further characterized expression
of microRNA and genes hMB-SLCs and this paper reports
a specific analysis of proteins, microRNAs, and genes that
regulate stem cell maintenance. Since the identification of
specific pathways supporting the survival of SLCs could open
new perspectives in cancer treatment, using the Genomatix
Pathway System (GePS) analysis, we also performed a deep
network pathway analysis with the aim of building regulatory
networks that include the crosstalk among microRNAs,
mRNAs, and proteins to better define SLCs specific signaling
components.
2. Materials and Methods
2.1. Materials. Unless otherwise indicated, media and sup-
plements were purchased from Gibco-Invitrogen (Carlsbad,
CA) and chemicals were purchased from Sigma-Aldrich (St.
Louis, MO).
2.2. Culture of hMB-SLCs. Human medulloblastoma sam-
ples (MB) were collected during surgical resection with
the approval of institutional review board as described
earlier [13]. Tissues were collected in Hank’s Balanced
Salt Solution (HBSS) supplemented with 0.5% glucose and
penicillin-streptomycin, grossly triturated with serological
pipette, and treated with DNAse I to a final concentration
of 0.04% for 20min. Subsequently, cell aggregates were
mechanically disrupted using pipettes of decreasing bore
size to obtain a single cell suspension. After dissociation
and centrifugation, cells were cultured as oncospheres in
selective medium, DMEM/F12 supplemented with 0.6%
glucose, 60mg/mL N-acetyl-L-cysteine, 2mg/mL heparin,
20 ng/mL NGF, 20 ng/mL bFGF (Peprotech, Rocky Hill,
NJ), 1x penicillin-streptomycin, and B27 supplement without
vitamin A. For differentiation studies, oncospheres were
mechanically dissociated and plated on D-poly-lysine coated
dishes in differentiation medium (DMEM/F12 with N2
supplement and 2mg/mL heparin, 0.6% glucose, 60mg/mL
N-acetyl-L-cysteine containing 1% fetal bovine serum, and
RA 8𝜇M) for 48 h. All samples were prepared in 3 biological
replicates for each point.
2.3. Immunochemical Analysis. Cells were lysed in Tris-HCl
pH 7.6, 50mM, deoxycholic acid sodium salt 0.5%, NaCl
140mM, NP40 1%, EDTA 5mM, NaF 100mM, Na pyrophos-
phate 2mM, and protease inhibitors. Lysates were separated
on 10% or 12% acrylamide gel and immunoblotted using
standard procedures. Rabbit anti-OCT4, #2750 (Cell Signal-
ing Technology Inc., Danvers, MA), rabbit anti-Nanog, PA1-
097 (ThermoFisher Scientific, Rockford, IL), mouse anti-𝛽-
3-Tubulin (TU-20), #4466 (Cell Signaling Technology Inc.),
mouse anti-GFAP, MAB360 (Merck Millipore, Darmstadt),
rabbit anti-HspA1A, sc-33575 (Santa Cruz Biotechnology,
CA), rabbit anti-PCNA, #13110 (Cell Signaling Technology
Inc.), rabbit anti-NPM, #3542 (Cell Signaling Technology
Inc.), mouse anti-GAPDH, ab8245 (AbCam, Cambridge,
UK), rabbit anti-Hsp60, #D307 (Cell Signaling Technol-
ogy Inc.), and HRP-conjugated secondary antisera (Santa
Cruz Biotechnology, CA) were used followed by enhanced
chemiluminescence (ECL Amersham, Amersham, UK) and
images were acquired using BioRad ChemiDoc MP Imaging
System (BioRad, Hercules, CA). Densitometric analysis was
performed using the BioRad associated Image Lab Software
(BioRad, Hercules, CA). Values are expressed as fold over
internal control, represented by GAPDH or Hsp60, in the
case of NPM, whose expressions were not significantly
modulated in the proteome profiles.
2.4. Bright Field Microscopy. For bright field acquisition,
oncospheres were plated on D-poly-lysine coated Lab-
Tek chamber slides and allowed to adhere for 3 h. RA-
differentiated MB cells (RA) were mechanically dissociated,
plated on D-poly-lysine coated Lab-Tek chamber slides, and
cultured in differentiating medium for 2 days and then
fixed with 4% paraformaldehyde for 10min at RT. Bright
field high-resolution images were acquired using a FV1200
MPE laser scanning confocal microscope (Olympus) with a
UPlanSAPO 60x/1.35 NA oil immersion objective.
2.5. RNA Isolation and Real-Time qPCR. RNA isolation was
performed as described previously [14]. cDNA synthesis
was performed using the High Capacity cDNA reverse
transcription kit from Applied Biosystems (AB, Foster City,
CA). Quantitative reverse transcription (qPCR) analysis of
OCT4, Nanog, Nestin, KLF4, 𝛽-3-Tubulin, GFAP, BMP4,
MSI1, BMI1, PCNA, CCNE1, CCNB1, CCND1, and MID1
mRNA expression was performed on cDNAs employing the
Applied Biosystems ViiA 7 Real-Time PCR System using
TaqMan gene expression assay according to the manufac-
turer’s instructions (AB). Each amplification reaction was
performed in triplicate, and the average of the three threshold
cycles was used to calculate the amount of transcripts in
the sample (SDS software, AB). mRNA quantification was
expressed, in arbitrary units, as the ratio of the sample
quantity to the calibrator or to the mean values of control
samples. All values were normalized to four endogenous
controls, GAPDH, 𝛽-2 microglobulin, Hprt, and Tbp.
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Figure 1: Experimental design and analysis of hMB-SLCs. Three biological cell replicates obtained by untreated and RA-treated cells were
compared for proteome, genes, and microRNAs expression patterns.
2.6. MicroRNA Expression Profiling, Microarray Data Anal-
ysis, and qPCR. Analysis of the expression profiling of 754
microRNAs was carried out on 3 replicates for each RNA
sample according to Applied Biosystems protocols (Foster
City, CA). This array detects the 754 most abundantly
expressed and best-characterized microRNAs in the Human
microRNA genome. The assay included RT with specific
primers followed by real-time qPCR using the TaqManArray
HumanmicroRNAA + B Cards set v3.0 and TaqMan univer-
sal master mix in an Applied Biosystems ViiA 7 Real-Time
PCR System. MicroRNA expression levels were normalized
to two different internal control small RNAs (RNU48 and U6
snRNA) obtaining similar results.The comparative threshold
cycle method was used to calculate the relative microRNA
expression. Statistical analysis of microRNAs differentially
expressed among samples was carried out by means of
StatMiner Software V5.0 (Integromics Inc., Waunakee, WI)
through the use of paired 𝑡-test (𝑝 < 0.05).
2.7. Pathway Analysis. The candidate proteins, microRNAs,
and genes were used as input in the GePS (Genomatix
Pathway System, Release 2.7.1, Genomatix Genome Analyzer
v3.30126) in order to investigate the connections between the
8 proteins, 22 microRNAs, and 7 genes. No extension of the
network was performed since our approach was to identify
connections between the above-mentioned entities without
external influence.
2.8. Bioinformatics and Statistical Analysis. Data reported in
this paper are the mean ± S.D. of at least three independent
experiments, each performed in triplicate. Unless otherwise
stated, statistical analysis was performed by the Student
𝑡-test and experimental data elaborated by means of
the GraphPad Prism 5 software (GraphPad Software
for Science, San Diego). Unsupervised clustering and
heat maps were generated in Gene-E (version 3.0.238,
http://www.broadinstitute.org/cancer/software/GENE-E/)
using microRNA expression levels as input. In Gene-E
the one minus Pearson correlation method was used for
clustering and the average linkage as a linkage method.
3. Results
3.1. Proteins andGenes Characterizing hMB-SLCs. To investi-
gate proteins and genes features of hMB-SLCs, three biologi-
cal cell replicates obtained by untreated andRA-treated hMB-
SLCs were analyzed (Figure 1). As shown in Figure 2(a), 48 h
after RA treatment hMB-SLCs displayed typical morpho-
logical changes of differentiated cells, compared to control
cells. In accordance with morphological changes, also the
expression of stemness and differentiation specific markers
was up- or downregulated in control and RA-treated cells,
respectively, both at protein (Figure 2(b)) and transcript
(Figures 2(c) and 2(d)) level.
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Figure 2: Morphology and characteristics of hMB-SLCs. (a) hMB-SLCs were cultured for 48 h in the absence or in the presence of 8 𝜇MRA
which induces SLCs differentiation, highlighted by morphological changes and cell adhesion. (b) Western blot analysis confirmed that 48 h
exposure of hMB-SLCs to 8 𝜇MRA induced a strong reduction in the stemnessmarkers Nanog andOCT4while increasing the differentiation
markers, 𝛽-3-Tubulin and GFAP. (c) qPCR analysis ofOCT4,Nanog,KLF4, 𝛽-3-Tubulin,GFAP, and BMP4was conducted before and after RA
treatment. mRNA expression levels are indicated as fold changes with respect to hMB-SLCs. (d) Gene expression of stemness, differentiation,
and proliferation markers in hMB-SLCs with respect to RA-treated cells. ∗ denotes 𝑝 < 0.05 versus hMB-SLCs, ∗∗ denotes 𝑝 < 0.01 versus
hMB-SLCs, and ∗ ∗ ∗ denotes 𝑝 < 0.001 versus hMB-SLCs.
In particular, among stemness genesNanog, Kruppel-Like
Factor 4 (KLF4), Nestin, and Octamer Binding Transcription
Factor 4 (OCT4) characterized stem cells analyzed while
BMP4,𝛽-3-Tubulin, andGFAP characterized RA-treated cells
(Figures 2(c) and 2(d)). Among proliferation genes, the two
markers significantly modulated at the transcript level were
Proliferating Cell Nuclear Antigen (PCNA) and Cyclin E1
(CCNE1), respectively, up- and downregulated, while Cyclin
B1 and Cyclin D1 (CCNB1, CCND1) expression was not
modified (Figure 2(d)).
3.2. MicroRNAs Patterns in hMB-SLCs. The three biolog-
ical cell replicates were further investigated to highlight
microRNA patterns (Figure 1).
Our analysis revealed 22 microRNAs (Figures 3(a) and
3(b)) differentially expressed after 48 h of RA treatment.
In order to endorse our results, we focused on 3 out of
22 microRNAs known to be involved in cell proliferation,
stemness maintenance, and tumor invasiveness for qPCR
validation (Figure 3(c)).Then, by usingmirPath (http://diana
.imis.athena-innovation.gr/DianaTools/index.php?r=mirpath/
index) we were able to identify the molecular and
biological functions mainly involved in the RA-induced
differentiation process (Figure 3(d) and Supplementary
Table 1 in Supplementary Material available online at http://
dx.doi.org/10.1155/2016/2683042).
3.3. MicroRNA Targets. MicroRNAs are known to regulate
gene expression at the posttranscriptional level and have
multitarget characteristics, being able to control groups of
genes; thus, we focused on the identification of all possible
target genes of the 22 differentially expressed microRNAs
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Figure 3: MicroRNA profiling of hMB-SLCs and RA-treated cells and qPCR validation. (a) Heatmap with unsupervised hierarchical
clustering was obtained for hMB-SLCs and their differentiated counterparts. Dendrogram which represents the results of the hierarchical
clustering analysis distinguishes hMB-SLCs from RA-treated ones. (b) Significantly up- or downregulated microRNAs in hMB-SLCs versus
RA-treated cells with the respective fold change and 𝑝 values are reported. (c) Single qPCR analysis of miR-195, miR-135b, and miR-145 was
conducted. MicroRNAs expression levels are expressed as fold change with respect to hMB-SLCs. ∗∗ denotes 𝑝 < 0.01 versus hMB-SLCs.
(d) Biological processes ranked according to the number of microRNAs involved in each process are assigned as in KEGG pathway.
(Figures 3(a) and 3(b)) by using miRTarBase (Supplementary
Table 2). Moreover, since microRNAs negatively regulate
mRNAs, we expected that increased microRNA expression
would be associated with targets that decreased in expression
and vice versa; among them, we deeply analyzed those that
could have a role in the regulation of proliferation and/
or differentiation of hMB-SLCs. In particular, miR-195 upreg-
ulated after RA treatment targeted CCNE1 that was accord-
ingly downregulated after RA-treatment. In addition also
miR-145, which belongs to the same family of miR-195, was
upregulated in RA-treated cells. Its targets, such as KLF4
and OCT4 [15], were downregulated after RA-treatment.
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Figure 4: Interaction network of microRNAs, proteins, and genes in hMB-SLCs by means of GePS analysis.
Table 1: Differentially regulated interaction between microRNAs
and genes.
MicroRNA MicroRNA foldchange (Log
10
) Target gene mRNA RQ
hsa-miR-135b −0.435 MID1 8.5
hsa-miR-145 0.533 KLF4 0.198
hsa-miR-195 0.309 CCNE1 0.445
Conversely miR-135b, which was downregulated after RA-
treatment, targeted Midline 1 Ring Finger Protein (MID1),
upregulated in RA-treated hMB-SLCs (Table 1).
3.4. MicroRNAs, Genes, and Proteomic Networks. Recently,
we investigated the proteomic profile of hMB-SLCs and their
RA-differentiated counterparts applying a label-free quanti-
tative proteomic analysis able to maximize the identification
capacities of the statistically differential spectral features
[8]. Thus, to identify networks of microRNAs, genes, and
proteins that could be involved in hMB-SLCs maintenance,
we considered the previously described proteomic profile of
hMB-SLCs [8] together with the new data reported in this
paper as input in a GePS analysis (Figure 4). In order to
endorse our proteomic results, by means of western blotting
we validated the 3 out of 68 proteins (Figure 5) derived from
[8] that connected with significantly deregulated microRNAs
and genes, feature of the analyzed stem cells. In particu-
lar, we concentrated on three subnetworks that could be
interestingly involved in the maintenance of hMB-SLCs
proliferation (Figures 6(a), 6(b), and 6(c)). In Figure 6(a) a
network includingmiR-195 and its proliferative targetCCNE1
is shown. In addition to CCNE1 also PCNA, another known
target of miR-195 [16] is included in the network. The second
network (Figure 6(b)) comprises miR-135b, its direct target
MID1, and Nucleophosmin (NPM), an important player in
cell proliferation and apoptosis [17]. Finally the third network
shows the link among the tumor suppressive microRNA,
miR-145 [18], KLF4, p65, and the Heat Shock 70 kDa Protein
(HspA1A) (Figure 6(c)).
4. Discussion
MB is under continuous study in order to define the signaling
pathways involved in its growth and progression and in order
to avoid overtreatment and therapy related side effects on the
developing brain [19]. However the existence of cancer stem
cells, which represent a resistant subpopulation, makes both
tumor treatment and eradicationmore difficult, raising a high
interest in the research of signaling that drives those cells.
In this study, we focused on the analysis of miRNome
and genes expression profile of hMB-SLCs with respect
to their RA-differentiated counterparts in order to identify
components that are specifically up- or downregulated and
thus may play a role in their maintenance. MicroRNAs
indeed are involved in the regulation of mRNA and protein
expression levels, concordantly modulated as shown in the
present study, even though they can also intervene in other
important regulatory mechanisms. Therefore we used the
GePS analysis in order to identify specific pathways that sup-
port proliferation and survival of hMB-SLCs or conversely
sustain hMB-SLCs differentiation in a more mature and less
aggressive phenotype.
In a recent study we revealed 68 proteins specific for
hMB-SLCs [8] and in this study we extended the analysis to
microRNAs and genes and identified 22microRNAs (Figures
3(a) and 3(b)) that were significantly modulated after RA-
treatment. First of all, in order to endorse our results, we
selected some biologically relevant microRNAs and proteins
and conducted specific single qPCR (Figure 3(c)) andwestern
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Figure 5: WB validation. (a) Western blot analysis of NPM, PCNA, and HspA1A in hMB-SLCs and in 48 h RA-treated cells. Hsp60 and
GAPDH were used as control for equal protein load. (b) Densitometric analysis confirmed the significant differential expression observed
by proteomic analysis. The protein expression, normalized to Hsp60 expression for NPM and GAPDH expression for the other proteins,
represents the mean ± SEM from three independent experiments. ∗ denotes 𝑝 < 0.05 versus hMB-SLCs.
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Figure 6: Subnetworks of microRNAs, proteins, and genes putatively involved in the maintenance of hMB-SLCs proliferation. (a) miR-195
has direct connections to CCNE1 that targets PCNA. (b) NPM1 (NPM) interacts withMID1 that targets the oncogenic microRNA, miR-135b.
(c) miR-145 regulates the stemness marker KLF4 that interacts both with p65 and with the heat-shock protein HspA1A.
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blotting analysis (Figures 5(a) and 5(b)) to confirm the quality
of the data obtained by using high-throughput technology
screening, as MS spectrometry [8] and microRNAs arrays.
Since our results indicated a good correlation among the
different technologies, we used mirPath (Figure 3(d) and
Supplementary Table 1) and GePS software (Figure 4) in
order to define the biological processes in which these dif-
ferentially expressed microRNAs and validated proteins were
both involved. The most interesting among the significant
biological processes that resulted from our analysis referred
to cancer cell activated pathways, such as mTOR, TGF𝛽,
and PI3K-Akt signaling, cell cycle regulation, cytoskeleton
remodeling, and energy metabolism. All these biological
events are already known to be deregulated not only in cancer
cells but also in cancer stem cells.
Subsequently, since our aim was the identification of
networks involved in hMB-SLCs maintenance, we used
differentially expressed microRNAs and proteins as input
and analyzed their relationship by using the GePS analysis
software (Figure 4). Focusing our attention on the network
we obtained, we uncovered three subnetworks that could
be interestingly involved in the maintenance of hMB-SLCs
proliferation (Figures 6(a), 6(b), and 6(c)). As shown in
Figure 6(a), miR-195, CCNE1, and PCNA are involved in
the first subnetwork. CCNE1 is a key regulator of cell
cycle promoting the progression to the G1 phase and the
entry in the S phase [20, 21]. Together with CCND1, which
leads to the hyperphosphorylation of the tumor suppressor
protein retinoblastoma (pRb) and to its dissociation of the
E2 promoter-binding protein dimerization partners (E2F)
from the pRb/E2F complex, CCNE1 is considered to be a key
oncogene and is overexpressed in breast, liver, lung, and brain
cancers [22, 23]. However, despite its role as an oncogene,
only recently it has been proposed in human glioma cells
a mechanism for the regulation of CCNE1 activity that
involves the miR-195 and leads to the reduction of pRb phos-
phorylation and to the downregulation of the proliferative
marker PCNA [16]. In our model, miR-195 was significantly
upregulated after hMB-SLCs differentiation, in contrast to
its direct target CCNE1, whose expression was significantly
reduced. As a consequence of the inhibition of hMB-SLCs
proliferation, also PCNA expression was strongly decreased.
Thus, our results point out that the mechanism of CCNE1
modulation by miR-195 and the subsequent reduction of
PCNA may be also involved in the regulation of hMB-SLCs
proliferation, suggesting that the inhibition and/or activation
of one or more players of this network could be of strong
interest in the clinical management of hMB-SLCs.
The second subnetwork (Figure 6(b)) includedmiR-135b,
MID1, and NPM (NPM1). In a recent high throughput study
conducted on 6 different pediatric SLCs, not only was miR-
135b significantly upregulated in the SLCs fraction compared
to each non-SLCs reference fraction but also its silencing
strongly inhibited their ability of self-renewal [24]. In addi-
tion, this microRNA has been shown to be overexpressed in
hMB compared to normal cerebellum [25] and to correlate
with poor prognosis and degree of malignancy in a number
of different tumors, such as colon cancer, ependymoma, and
hepatocellular carcinoma [26–29]. One of itsmost interesting
targets with the aim of unraveling tumor biology is the
microtubule-associated ubiquitin E3 ligase MID1, whose
downregulation in human solid tumors has been associated
with a more aggressive phenotype and with an increased
invasiveness [30]. Furthermore a direct physical interaction
between MID1 and NPM has been lately reported [31], a
multifunctional nucleolar phosphoprotein required for the
assembly of ribosomes, that has also been described as a MB
resistance marker and whose expression is correlated to the
ability of MB to survive in unfavorable growth conditions
[19]. Interestingly our results showed a significant reduction
of both miR-135b and NPM expression after RA-induced
differentiation associatedwith a strong upregulation ofMID1,
highlighting their negative correlation compared to this gene
and suggesting that also in this case the pharmacological
regulation of these players could be very useful in order to
control MB growth.
Finally the third subnetwork (Figure 6(c)) consisted of
four different players,miR-145,KLF4, p65, andHspA1A.MiR-
145 has been recently described as a dominant player in
the differentiation process of human embryonic stem cells
(hESCs). In these cells, miR-145 significantly increased dur-
ing differentiation and acted through the posttranscriptional
downregulation ofOCT4, SOX2, andKLF4 [15]. As described
in hESCs, our results confirmed that also in hMB-SLCs
there was a significant increase of miR-145 after 48 h of RA-
treatment and a strong decrease of some of these stemness
markers, as shown in Figures 2(b), 2(c), and 2(d). In addition
KLF4, a well-known pluripotency factor [32] which is impli-
cated in glioblastoma stem cells proliferation, migration,
and invasion [33] has also been demonstrated to physically
interact with p65, amember of theNF-𝜅B family of transcrip-
tion factors involved in the regulation of a wide variety of bio-
logical responses and with a pivotal role in oncogenesis [34],
in the induction of amacrophage-mediated proinflammatory
pathway activation [35]. Very recently we have shown that
the NF-𝜅B complex was strongly activated in hMB-SLCs and
hypothesized its connection with the molecular chaperone
HspA1A, which increased in hMB-SLCs and significantly
decreased after RA-induced differentiation [8]. Thus, this
third network corroborates our recent hypothesis and under-
lines the fact that this microRNA, repressing some core
pluripotency factors such as OCT4 and KLF4, is crucially
involved in the modulation of the differentiation pathway
progression of cancer stem cells.
5. Conclusions
Taken together, our results report the analysis of microRNAs,
genes, and proteins that are significantly regulated in hMB-
SLCs with respect to their RA-differentiated counterparts.
Many of these microRNAs through a direct mRNA interac-
tion may act on different proteins, such as NPM, PCNA, p65,
and HspA1A, with the creation of networks involved in the
induction of aberrant cell growth and proliferation other than
programmed cell death resistance linked to SLCs features.
In conclusion, our findings could open new perspectives for
prognostic and therapeutic intervention on MB.
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